Skip to main content
. 2020 Nov 16;2:602236. doi: 10.3389/fmedt.2020.602236

Figure 10.

Figure 10

Scalable THL manufacturing using ethanol dilution to encapsulate the plasmid DNA within small 100–150 nm vesicles, and using tangential flow filtration (TFF) with a 100 kDa molecular weight cut-off (MWCO) to remove the nuclease and ethanol, and a second TFF with a 300 kDa MWCO to remove the unconjugated MAb. The final THL formulation is sterile filtered, and lyophilized for long term storage. hrDNaseI, human recombinant DNase I.